View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMETabolic EXplorer 過去の業績過去 基準チェック /06METabolic EXplorerの収益は年間平均-239.2%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間4.4% 36.4%割合で 減少しています。主要情報-239.21%収益成長率-166.54%EPS成長率Chemicals 業界の成長12.41%収益成長率-36.39%株主資本利益率-51.87%ネット・マージン-29.34%前回の決算情報30 Jun 2023最近の業績更新Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107%, compared to a 8.2% growth forecast for the industry in Germany.Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.すべての更新を表示Recent updatesお知らせ • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares IndexNew Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).New Risk • Oct 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.7m market cap, or US$12.4m).Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.お知らせ • Dec 28METabolic EXplorer S.A. announced that it has received €8 million in fundingMETabolic EXplorer S.A. announced that it has raised €8 million in a round of funding on December 27, 2022.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €4.54, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 9x in the Chemicals industry in Germany. Total returns to shareholders of 175% over the past three years.Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107%, compared to a 8.2% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 20% share price gain to €5.29, the stock trades at a forward P/E ratio of 315x. Average forward P/E is 10x in the Chemicals industry in Germany. Total returns to shareholders of 252% over the past three years.Valuation Update With 7 Day Price Move • Nov 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to €6.31, the stock trades at a trailing P/E ratio of 3.7x. Average forward P/E is 12x in the Chemicals industry in Germany. Total returns to shareholders of 260% over the past three years.お知らせ • May 05METabolic EXplorer S.A. (ENXTPA:METEX) completed the acquisition of Ajinomoto Animal Nutrition Europe S.A.S. from Ajinomoto Co., Inc. (TSE:2802).METabolic EXplorer S.A. (ENXTPA:METEX) signed a share purchase agreement to acquire Ajinomoto Animal Nutrition Europe S.A.S. from Ajinomoto Co., Inc. (TSE:2802) for €15 million on April 15, 2021. Consideration would be paid in two installments, €8 million upon closing and €7 million within 6 months of closing. There is no conditions precedent and transaction is now expected to be completed in the coming weeks. METabolic EXplorer S.A. (ENXTPA:METEX) completed the acquisition of Ajinomoto Animal Nutrition Europe S.A.S. from Ajinomoto Co., Inc. (TSE:2802) on May 3, 2021. AANE will officially take the name of METEX NØØVISTAGO in the coming weeks. Benjamin Gonzalez, Founder and CEO of METabolic EXplorer, was appointed Chairman of METEX NØØVISTAGO on April 28, 2021. David Demeestere was appointed as Deputy Managing Director of Industrial Operations of the Group. Chairman of AANE, David DEMEESTERE also took over the General Management of METEX NØØVISTAGO.Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).Is New 90 Day High Low • Mar 01New 90-day high: €4.70The company is up 104% from its price of €2.30 on 01 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.Is New 90 Day High Low • Feb 08New 90-day high: €3.10The company is up 82% from its price of €1.71 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.Is New 90 Day High Low • Jan 23New 90-day high: €2.89The company is up 66% from its price of €1.74 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period.Is New 90 Day High Low • Jan 06New 90-day high: €2.72The company is up 63% from its price of €1.67 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.Is New 90 Day High Low • Nov 27New 90-day high: €1.96The company is up 7.0% from its price of €1.83 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: €1.61The company is down 12% from its price of €1.82 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.収支内訳METabolic EXplorer の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:7ME 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 23168-4930931 Mar 23198-5032931 Dec 22228-51331030 Sep 22246-33331030 Jun 22264-15331031 Mar 222183429931 Dec 211728324830 Sep 211057917730 Jun 2138759631 Mar 2120337631 Dec 202-94630 Sep 202-95630 Jun 202-85631 Mar 202-85631 Dec 192-85530 Sep 193-95530 Jun 193-95531 Mar 194-85531 Dec 186-65530 Sep 186-95630 Jun 187-115631 Mar 187-114631 Dec 177-114630 Sep 176-14630 Jun 17684631 Mar 17574731 Dec 16474730 Sep 16404730 Jun 164-74731 Mar 163-74731 Dec 153-74630 Sep 154-74630 Jun 154-64531 Mar 155-54531 Dec 146-44530 Sep 144-34430 Jun 143-24331 Mar 142-34231 Dec 131-44130 Sep 131-741質の高い収益: 7MEは現在利益が出ていません。利益率の向上: 7MEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 7MEの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: 7MEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 7MEは利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -13.5% ) と比較することは困難です。株主資本利益率高いROE: 7MEは現在利益が出ていないため、自己資本利益率 ( -51.87% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/03 18:19終値2024/05/06 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋METabolic EXplorer S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Arsene GuekamCIC Market Solutions (ESN)Nicolas RoyotPortzamparc BNP ParibasChristophe Dombu YoutaPortzamparc BNP Paribas
Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.
Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107%, compared to a 8.2% growth forecast for the industry in Germany.
Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.
お知らせ • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares Index
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).
New Risk • Oct 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.7m market cap, or US$12.4m).
Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 28METabolic EXplorer S.A. announced that it has received €8 million in fundingMETabolic EXplorer S.A. announced that it has raised €8 million in a round of funding on December 27, 2022.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.2% growth forecast for the Chemicals industry in Germany.
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €4.54, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 9x in the Chemicals industry in Germany. Total returns to shareholders of 175% over the past three years.
Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107%, compared to a 8.2% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 20% share price gain to €5.29, the stock trades at a forward P/E ratio of 315x. Average forward P/E is 10x in the Chemicals industry in Germany. Total returns to shareholders of 252% over the past three years.
Valuation Update With 7 Day Price Move • Nov 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to €6.31, the stock trades at a trailing P/E ratio of 3.7x. Average forward P/E is 12x in the Chemicals industry in Germany. Total returns to shareholders of 260% over the past three years.
お知らせ • May 05METabolic EXplorer S.A. (ENXTPA:METEX) completed the acquisition of Ajinomoto Animal Nutrition Europe S.A.S. from Ajinomoto Co., Inc. (TSE:2802).METabolic EXplorer S.A. (ENXTPA:METEX) signed a share purchase agreement to acquire Ajinomoto Animal Nutrition Europe S.A.S. from Ajinomoto Co., Inc. (TSE:2802) for €15 million on April 15, 2021. Consideration would be paid in two installments, €8 million upon closing and €7 million within 6 months of closing. There is no conditions precedent and transaction is now expected to be completed in the coming weeks. METabolic EXplorer S.A. (ENXTPA:METEX) completed the acquisition of Ajinomoto Animal Nutrition Europe S.A.S. from Ajinomoto Co., Inc. (TSE:2802) on May 3, 2021. AANE will officially take the name of METEX NØØVISTAGO in the coming weeks. Benjamin Gonzalez, Founder and CEO of METabolic EXplorer, was appointed Chairman of METEX NØØVISTAGO on April 28, 2021. David Demeestere was appointed as Deputy Managing Director of Industrial Operations of the Group. Chairman of AANE, David DEMEESTERE also took over the General Management of METEX NØØVISTAGO.
Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).
Is New 90 Day High Low • Mar 01New 90-day high: €4.70The company is up 104% from its price of €2.30 on 01 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Feb 08New 90-day high: €3.10The company is up 82% from its price of €1.71 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period.
Is New 90 Day High Low • Jan 23New 90-day high: €2.89The company is up 66% from its price of €1.74 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period.
Is New 90 Day High Low • Jan 06New 90-day high: €2.72The company is up 63% from its price of €1.67 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.
Is New 90 Day High Low • Nov 27New 90-day high: €1.96The company is up 7.0% from its price of €1.83 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: €1.61The company is down 12% from its price of €1.82 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.